Jennifer Patnaik
Concepts (407)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cataract | 18 | 2024 | 220 | 3.970 |
Why?
| | Visual Acuity | 25 | 2025 | 424 | 3.730 |
Why?
| | Macular Degeneration | 14 | 2024 | 166 | 2.930 |
Why?
| | Geographic Atrophy | 11 | 2025 | 79 | 2.860 |
Why?
| | Phacoemulsification | 14 | 2025 | 119 | 2.650 |
Why?
| | Wet Macular Degeneration | 7 | 2025 | 57 | 2.190 |
Why?
| | Diabetic Retinopathy | 13 | 2024 | 190 | 2.170 |
Why?
| | Lenses, Intraocular | 6 | 2022 | 45 | 1.900 |
Why?
| | Intraocular Pressure | 11 | 2025 | 306 | 1.610 |
Why?
| | Ophthalmology | 6 | 2025 | 102 | 1.500 |
Why?
| | Cataract Extraction | 10 | 2024 | 105 | 1.440 |
Why?
| | Glaucoma | 8 | 2025 | 234 | 1.190 |
Why?
| | Registries | 8 | 2025 | 2054 | 1.190 |
Why?
| | Optometrists | 2 | 2025 | 7 | 1.160 |
Why?
| | Optometry | 2 | 2025 | 9 | 1.160 |
Why?
| | Keratomileusis, Laser In Situ | 3 | 2024 | 20 | 1.120 |
Why?
| | Retinal Detachment | 6 | 2023 | 74 | 0.990 |
Why?
| | Tomography, Optical Coherence | 9 | 2025 | 224 | 0.980 |
Why?
| | Photorefractive Keratectomy | 2 | 2024 | 20 | 0.970 |
Why?
| | Retinopathy of Prematurity | 3 | 2022 | 156 | 0.950 |
Why?
| | Myopia | 7 | 2024 | 55 | 0.940 |
Why?
| | Keratotomy, Radial | 2 | 2022 | 10 | 0.940 |
Why?
| | Retrospective Studies | 52 | 2025 | 15922 | 0.850 |
Why?
| | Fluorescein Angiography | 8 | 2025 | 163 | 0.840 |
Why?
| | Burnout, Professional | 3 | 2025 | 450 | 0.840 |
Why?
| | Refraction, Ocular | 6 | 2024 | 43 | 0.800 |
Why?
| | Follow-Up Studies | 21 | 2025 | 5165 | 0.780 |
Why?
| | Capsule Opacification | 2 | 2021 | 22 | 0.750 |
Why?
| | Intraoperative Complications | 6 | 2024 | 148 | 0.750 |
Why?
| | Humans | 114 | 2025 | 139062 | 0.740 |
Why?
| | Eye Diseases | 2 | 2020 | 90 | 0.730 |
Why?
| | Presbyopia | 1 | 2022 | 15 | 0.730 |
Why?
| | Retinal Drusen | 4 | 2024 | 31 | 0.720 |
Why?
| | Uveitis | 4 | 2025 | 146 | 0.720 |
Why?
| | Aged, 80 and over | 26 | 2025 | 7698 | 0.720 |
Why?
| | Posterior Capsulotomy | 1 | 2021 | 7 | 0.720 |
Why?
| | Posterior Capsule of the Lens | 1 | 2021 | 11 | 0.710 |
Why?
| | Trabeculectomy | 5 | 2025 | 72 | 0.710 |
Why?
| | Lasers, Solid-State | 1 | 2021 | 22 | 0.700 |
Why?
| | Aged | 46 | 2025 | 24236 | 0.700 |
Why?
| | National Eye Institute (U.S.) | 1 | 2020 | 6 | 0.690 |
Why?
| | Automobile Driving | 2 | 2022 | 148 | 0.660 |
Why?
| | Glaucoma, Open-Angle | 4 | 2023 | 101 | 0.640 |
Why?
| | Dementia | 1 | 2023 | 264 | 0.640 |
Why?
| | Retinal Neovascularization | 1 | 2019 | 28 | 0.630 |
Why?
| | Laser Therapy | 1 | 2021 | 129 | 0.630 |
Why?
| | Colorado | 21 | 2025 | 4532 | 0.620 |
Why?
| | Female | 68 | 2025 | 74074 | 0.610 |
Why?
| | Vitrectomy | 6 | 2025 | 76 | 0.600 |
Why?
| | Postoperative Complications | 6 | 2024 | 2738 | 0.590 |
Why?
| | Surveys and Questionnaires | 12 | 2025 | 5892 | 0.590 |
Why?
| | Estrogen Replacement Therapy | 1 | 2019 | 148 | 0.580 |
Why?
| | Lens, Crystalline | 1 | 2020 | 131 | 0.580 |
Why?
| | Lasers, Excimer | 3 | 2024 | 29 | 0.560 |
Why?
| | Male | 61 | 2025 | 68324 | 0.540 |
Why?
| | Metformin | 1 | 2021 | 334 | 0.540 |
Why?
| | Strabismus | 3 | 2023 | 61 | 0.540 |
Why?
| | West Nile Fever | 3 | 2011 | 53 | 0.520 |
Why?
| | Internal Medicine | 1 | 2019 | 273 | 0.510 |
Why?
| | Emergency Medicine | 1 | 2019 | 237 | 0.510 |
Why?
| | Middle Aged | 35 | 2025 | 33864 | 0.480 |
Why?
| | Prevalence | 7 | 2025 | 2746 | 0.480 |
Why?
| | Complement Activation | 4 | 2025 | 407 | 0.480 |
Why?
| | Self Report | 2 | 2022 | 840 | 0.460 |
Why?
| | Family Practice | 1 | 2019 | 462 | 0.460 |
Why?
| | Breast Neoplasms | 3 | 2011 | 2294 | 0.440 |
Why?
| | Lens Implantation, Intraocular | 5 | 2022 | 67 | 0.430 |
Why?
| | Cornea | 3 | 2025 | 149 | 0.420 |
Why?
| | Biomarkers | 9 | 2025 | 4115 | 0.420 |
Why?
| | Multimodal Imaging | 2 | 2025 | 117 | 0.410 |
Why?
| | Internet | 4 | 2023 | 674 | 0.410 |
Why?
| | Commerce | 2 | 2013 | 81 | 0.400 |
Why?
| | Diabetes Mellitus | 5 | 2024 | 1055 | 0.400 |
Why?
| | Vitreous Body | 4 | 2022 | 121 | 0.390 |
Why?
| | Fluocinolone Acetonide | 2 | 2023 | 15 | 0.390 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2024 | 551 | 0.380 |
Why?
| | Risk Factors | 14 | 2025 | 10426 | 0.370 |
Why?
| | Smoking Prevention | 1 | 2013 | 182 | 0.370 |
Why?
| | Ophthalmologic Surgical Procedures | 2 | 2025 | 82 | 0.370 |
Why?
| | Tobacco Products | 1 | 2013 | 132 | 0.370 |
Why?
| | Macula Lutea | 2 | 2023 | 21 | 0.370 |
Why?
| | United States | 17 | 2025 | 15065 | 0.350 |
Why?
| | Disease Notification | 2 | 2011 | 16 | 0.350 |
Why?
| | Retinal Diseases | 2 | 2023 | 96 | 0.350 |
Why?
| | Lens Capsule, Crystalline | 2 | 2021 | 13 | 0.340 |
Why?
| | Cross-Sectional Studies | 10 | 2025 | 5537 | 0.340 |
Why?
| | Artificial Intelligence | 2 | 2024 | 295 | 0.340 |
Why?
| | Angiogenesis Inhibitors | 2 | 2023 | 230 | 0.330 |
Why?
| | Complement Factor B | 2 | 2022 | 109 | 0.320 |
Why?
| | Eye Injuries | 2 | 2021 | 52 | 0.310 |
Why?
| | Comorbidity | 2 | 2011 | 1656 | 0.310 |
Why?
| | Tonometry, Ocular | 3 | 2025 | 98 | 0.310 |
Why?
| | Complement System Proteins | 3 | 2022 | 321 | 0.300 |
Why?
| | Treatment Outcome | 11 | 2025 | 10961 | 0.290 |
Why?
| | Diabetes Mellitus, Type 2 | 4 | 2023 | 2514 | 0.290 |
Why?
| | Laser Coagulation | 2 | 2025 | 71 | 0.270 |
Why?
| | Hepatitis A | 2 | 2011 | 26 | 0.270 |
Why?
| | Bangladesh | 3 | 2022 | 56 | 0.270 |
Why?
| | West Nile virus | 1 | 2007 | 42 | 0.270 |
Why?
| | Time Factors | 7 | 2025 | 6885 | 0.260 |
Why?
| | Health Promotion | 1 | 2013 | 745 | 0.260 |
Why?
| | Refractive Errors | 2 | 2024 | 33 | 0.260 |
Why?
| | Local Government | 1 | 2006 | 27 | 0.250 |
Why?
| | Choroid | 2 | 2024 | 63 | 0.250 |
Why?
| | Restaurants | 1 | 2006 | 25 | 0.250 |
Why?
| | Vision Disorders | 3 | 2022 | 156 | 0.250 |
Why?
| | Prospective Studies | 7 | 2025 | 7660 | 0.250 |
Why?
| | Chronic Disease | 2 | 2011 | 1802 | 0.240 |
Why?
| | Scleritis | 2 | 2025 | 24 | 0.240 |
Why?
| | Mass Screening | 2 | 2024 | 1287 | 0.240 |
Why?
| | Public Health Administration | 1 | 2006 | 74 | 0.240 |
Why?
| | Chemokine CCL5 | 2 | 2023 | 43 | 0.230 |
Why?
| | Ciliary Body | 1 | 2025 | 39 | 0.230 |
Why?
| | Pilocarpine | 1 | 2025 | 16 | 0.230 |
Why?
| | Keratoconus | 1 | 2025 | 23 | 0.230 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 1 | 2024 | 6 | 0.220 |
Why?
| | Glucocorticoids | 3 | 2024 | 532 | 0.220 |
Why?
| | Withholding Treatment | 1 | 2025 | 78 | 0.220 |
Why?
| | Quality of Life | 5 | 2023 | 2954 | 0.220 |
Why?
| | Surgery, Plastic | 1 | 2025 | 46 | 0.220 |
Why?
| | Occupational Stress | 1 | 2025 | 42 | 0.220 |
Why?
| | Education, Distance | 1 | 2025 | 53 | 0.220 |
Why?
| | Retinoblastoma | 1 | 2024 | 40 | 0.220 |
Why?
| | Birth Weight | 3 | 2022 | 512 | 0.220 |
Why?
| | Aberrometry | 2 | 2021 | 9 | 0.210 |
Why?
| | Gestational Age | 3 | 2022 | 922 | 0.210 |
Why?
| | Infant | 10 | 2025 | 9576 | 0.210 |
Why?
| | Disease Progression | 4 | 2025 | 2741 | 0.210 |
Why?
| | Optics and Photonics | 2 | 2021 | 42 | 0.210 |
Why?
| | Telemedicine | 2 | 2024 | 867 | 0.210 |
Why?
| | Adult | 22 | 2025 | 38389 | 0.210 |
Why?
| | Feasibility Studies | 2 | 2024 | 977 | 0.200 |
Why?
| | Macular Edema | 1 | 2023 | 45 | 0.200 |
Why?
| | Homosexuality, Male | 2 | 2020 | 193 | 0.200 |
Why?
| | Postoperative Period | 5 | 2025 | 358 | 0.200 |
Why?
| | Job Satisfaction | 1 | 2025 | 220 | 0.200 |
Why?
| | Insulins | 1 | 2023 | 37 | 0.200 |
Why?
| | Eye Burns | 1 | 2022 | 14 | 0.200 |
Why?
| | Vision, Low | 1 | 2022 | 17 | 0.190 |
Why?
| | Cohort Studies | 6 | 2022 | 5736 | 0.190 |
Why?
| | Endoscopy | 1 | 2025 | 320 | 0.190 |
Why?
| | Eyelid Diseases | 1 | 2022 | 22 | 0.190 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2023 | 83 | 0.190 |
Why?
| | Compartment Syndromes | 1 | 2022 | 29 | 0.190 |
Why?
| | Eyeglasses | 1 | 2022 | 22 | 0.190 |
Why?
| | Odds Ratio | 4 | 2019 | 1084 | 0.180 |
Why?
| | Incidence | 5 | 2022 | 2836 | 0.180 |
Why?
| | Corneal Ulcer | 1 | 2022 | 21 | 0.180 |
Why?
| | Retinal Perforations | 1 | 2022 | 19 | 0.180 |
Why?
| | Clothing | 1 | 2022 | 22 | 0.180 |
Why?
| | Patient Satisfaction | 2 | 2024 | 683 | 0.180 |
Why?
| | Ocular Hypertension | 1 | 2022 | 67 | 0.180 |
Why?
| | Weapons | 1 | 2021 | 9 | 0.170 |
Why?
| | Civil Disorders | 1 | 2021 | 8 | 0.170 |
Why?
| | Neonatal Screening | 1 | 2022 | 167 | 0.170 |
Why?
| | Political Activism | 1 | 2021 | 9 | 0.170 |
Why?
| | Refractive Surgical Procedures | 1 | 2021 | 7 | 0.170 |
Why?
| | Eye Banks | 1 | 2020 | 6 | 0.170 |
Why?
| | Corneal Transplantation | 1 | 2020 | 13 | 0.170 |
Why?
| | Sickness Impact Profile | 1 | 2020 | 57 | 0.170 |
Why?
| | Glaucoma Drainage Implants | 1 | 2021 | 45 | 0.170 |
Why?
| | Perception | 2 | 2021 | 368 | 0.170 |
Why?
| | Glycation End Products, Advanced | 1 | 2021 | 83 | 0.170 |
Why?
| | Posterior Capsular Rupture, Ocular | 1 | 2020 | 6 | 0.170 |
Why?
| | Accidents, Traffic | 1 | 2022 | 183 | 0.170 |
Why?
| | SEER Program | 2 | 2011 | 220 | 0.160 |
Why?
| | Neurodegenerative Diseases | 1 | 2022 | 138 | 0.160 |
Why?
| | Language | 1 | 2023 | 303 | 0.160 |
Why?
| | Scleral Buckling | 1 | 2019 | 18 | 0.160 |
Why?
| | Retinal Hemorrhage | 1 | 2019 | 22 | 0.160 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2019 | 14 | 0.160 |
Why?
| | Health Status Disparities | 1 | 2023 | 299 | 0.160 |
Why?
| | Legislation, Drug | 1 | 2020 | 83 | 0.160 |
Why?
| | Protective Factors | 1 | 2019 | 95 | 0.160 |
Why?
| | Oculomotor Muscles | 1 | 2020 | 74 | 0.160 |
Why?
| | Infant, Newborn | 5 | 2022 | 6152 | 0.160 |
Why?
| | Head Injuries, Closed | 1 | 2019 | 48 | 0.150 |
Why?
| | Child | 10 | 2025 | 21906 | 0.150 |
Why?
| | Hepatitis C | 1 | 2022 | 277 | 0.150 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2019 | 75 | 0.150 |
Why?
| | Risk Assessment | 3 | 2019 | 3469 | 0.150 |
Why?
| | Complement Membrane Attack Complex | 1 | 2019 | 39 | 0.150 |
Why?
| | Accreditation | 1 | 2019 | 90 | 0.150 |
Why?
| | Specialization | 1 | 2020 | 148 | 0.150 |
Why?
| | Complement C3a | 1 | 2019 | 42 | 0.150 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.150 |
Why?
| | Cardiovascular Diseases | 1 | 2011 | 2057 | 0.150 |
Why?
| | Refugees | 1 | 2020 | 78 | 0.150 |
Why?
| | Choroidal Neovascularization | 1 | 2019 | 56 | 0.150 |
Why?
| | Down Syndrome | 1 | 2025 | 486 | 0.140 |
Why?
| | Patient Care | 1 | 2019 | 114 | 0.140 |
Why?
| | Curriculum | 1 | 2025 | 1010 | 0.140 |
Why?
| | Case-Control Studies | 3 | 2022 | 3584 | 0.140 |
Why?
| | Medical Marijuana | 1 | 2020 | 123 | 0.140 |
Why?
| | Infant, Premature | 1 | 2022 | 580 | 0.140 |
Why?
| | Glaucoma, Angle-Closure | 1 | 2018 | 17 | 0.140 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 279 | 0.140 |
Why?
| | Trabecular Meshwork | 1 | 2018 | 79 | 0.140 |
Why?
| | Sexually Transmitted Diseases | 3 | 2004 | 163 | 0.140 |
Why?
| | Proto-Oncogene Proteins B-raf | 1 | 2019 | 222 | 0.130 |
Why?
| | Marijuana Smoking | 1 | 2020 | 260 | 0.130 |
Why?
| | Marijuana Use | 1 | 2020 | 207 | 0.130 |
Why?
| | Healthcare Disparities | 1 | 2023 | 661 | 0.120 |
Why?
| | Clinical Competence | 2 | 2025 | 1140 | 0.120 |
Why?
| | Young Adult | 5 | 2025 | 13341 | 0.120 |
Why?
| | Recovery of Function | 1 | 2019 | 666 | 0.120 |
Why?
| | Logistic Models | 2 | 2019 | 2089 | 0.120 |
Why?
| | Disease Management | 1 | 2019 | 620 | 0.120 |
Why?
| | Population Surveillance | 2 | 2011 | 480 | 0.120 |
Why?
| | Inflammation | 3 | 2023 | 2858 | 0.110 |
Why?
| | Education, Medical, Graduate | 1 | 2019 | 495 | 0.110 |
Why?
| | Proportional Hazards Models | 2 | 2024 | 1286 | 0.110 |
Why?
| | Fundus Oculi | 2 | 2025 | 73 | 0.110 |
Why?
| | Child, Preschool | 7 | 2025 | 11142 | 0.110 |
Why?
| | Disease Outbreaks | 2 | 2008 | 417 | 0.100 |
Why?
| | Retinal Pigment Epithelium | 2 | 2024 | 76 | 0.100 |
Why?
| | Condoms | 2 | 2004 | 102 | 0.100 |
Why?
| | Physicians | 1 | 2022 | 929 | 0.100 |
Why?
| | Adolescent | 8 | 2025 | 21561 | 0.100 |
Why?
| | Sexual Behavior | 4 | 2004 | 487 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1121 | 0.100 |
Why?
| | Melanoma | 1 | 2019 | 766 | 0.100 |
Why?
| | Medicare | 2 | 2024 | 790 | 0.090 |
Why?
| | Hypoglycemic Agents | 1 | 2021 | 1307 | 0.090 |
Why?
| | Skin Neoplasms | 1 | 2019 | 854 | 0.090 |
Why?
| | Axial Length, Eye | 2 | 2024 | 15 | 0.090 |
Why?
| | Tertiary Healthcare | 2 | 2022 | 34 | 0.090 |
Why?
| | Immunologic Factors | 2 | 2024 | 243 | 0.090 |
Why?
| | Diagnostic Errors | 1 | 2011 | 174 | 0.080 |
Why?
| | Shellfish Poisoning | 1 | 2009 | 1 | 0.080 |
Why?
| | Vibrio Infections | 1 | 2009 | 2 | 0.080 |
Why?
| | Primary Prevention | 1 | 2011 | 198 | 0.080 |
Why?
| | Shellfish | 1 | 2009 | 6 | 0.080 |
Why?
| | Food Industry | 1 | 2009 | 16 | 0.080 |
Why?
| | Food Microbiology | 1 | 2009 | 72 | 0.080 |
Why?
| | Cause of Death | 1 | 2011 | 426 | 0.080 |
Why?
| | Internship and Residency | 1 | 2019 | 1180 | 0.070 |
Why?
| | Kaplan-Meier Estimate | 1 | 2011 | 903 | 0.070 |
Why?
| | Mortality | 1 | 2011 | 360 | 0.070 |
Why?
| | Academic Medical Centers | 2 | 2022 | 512 | 0.070 |
Why?
| | Cryptosporidiosis | 1 | 2008 | 22 | 0.070 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 2162 | 0.070 |
Why?
| | Anti-Inflammatory Agents | 2 | 2022 | 475 | 0.070 |
Why?
| | Disease Reservoirs | 1 | 2007 | 25 | 0.070 |
Why?
| | Maternal-Child Health Centers | 1 | 2007 | 9 | 0.070 |
Why?
| | Culicidae | 1 | 2007 | 35 | 0.070 |
Why?
| | Sentinel Surveillance | 1 | 2007 | 48 | 0.070 |
Why?
| | Health Services Administration | 1 | 2007 | 8 | 0.070 |
Why?
| | Gastroenteritis | 1 | 2008 | 68 | 0.070 |
Why?
| | Relief Work | 1 | 2007 | 19 | 0.070 |
Why?
| | Chickens | 1 | 2007 | 189 | 0.070 |
Why?
| | Telephone | 1 | 2008 | 181 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 856 | 0.070 |
Why?
| | Geography | 1 | 2007 | 203 | 0.070 |
Why?
| | Birds | 1 | 2007 | 97 | 0.070 |
Why?
| | Horses | 1 | 2007 | 197 | 0.060 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2023 | 3629 | 0.060 |
Why?
| | Health Care Surveys | 1 | 2008 | 565 | 0.060 |
Why?
| | Disasters | 1 | 2007 | 100 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2044 | 0.060 |
Why?
| | Immunoglobulins | 1 | 2006 | 169 | 0.060 |
Why?
| | Environment | 1 | 2007 | 341 | 0.060 |
Why?
| | Smoking | 1 | 2013 | 1607 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1404 | 0.060 |
Why?
| | Corneal Topography | 1 | 2025 | 25 | 0.060 |
Why?
| | Miotics | 1 | 2025 | 6 | 0.060 |
Why?
| | Muscarinic Agonists | 1 | 2025 | 15 | 0.060 |
Why?
| | Azathioprine | 1 | 2025 | 49 | 0.060 |
Why?
| | Adalimumab | 1 | 2025 | 53 | 0.060 |
Why?
| | Immunization Programs | 1 | 2007 | 218 | 0.060 |
Why?
| | Ganglionic Stimulants | 1 | 2005 | 15 | 0.060 |
Why?
| | Tomography | 1 | 2025 | 43 | 0.060 |
Why?
| | Lubricant Eye Drops | 1 | 2024 | 9 | 0.060 |
Why?
| | Ontario | 1 | 2024 | 95 | 0.060 |
Why?
| | Infliximab | 1 | 2025 | 112 | 0.060 |
Why?
| | Needs Assessment | 1 | 2007 | 381 | 0.060 |
Why?
| | Mycophenolic Acid | 1 | 2025 | 118 | 0.050 |
Why?
| | Retinal Neoplasms | 1 | 2024 | 36 | 0.050 |
Why?
| | Rwanda | 1 | 2024 | 30 | 0.050 |
Why?
| | Conjunctivitis | 1 | 2024 | 31 | 0.050 |
Why?
| | Patient Discharge | 1 | 2011 | 909 | 0.050 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 78 | 0.050 |
Why?
| | Capacity Building | 1 | 2024 | 61 | 0.050 |
Why?
| | Vision Tests | 1 | 2023 | 18 | 0.050 |
Why?
| | Methotrexate | 1 | 2025 | 255 | 0.050 |
Why?
| | Hospitals, County | 1 | 2023 | 11 | 0.050 |
Why?
| | Attitude to Health | 1 | 2007 | 458 | 0.050 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2011 | 1030 | 0.050 |
Why?
| | Postoperative Care | 1 | 2025 | 274 | 0.050 |
Why?
| | Observational Studies as Topic | 1 | 2023 | 119 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2011 | 1088 | 0.050 |
Why?
| | Health Surveys | 2 | 2021 | 521 | 0.050 |
Why?
| | Interleukin-4 | 1 | 2023 | 214 | 0.050 |
Why?
| | Tobacco Use Disorder | 1 | 2005 | 245 | 0.050 |
Why?
| | Complement Factor I | 1 | 2022 | 12 | 0.050 |
Why?
| | Gonorrhea | 1 | 2003 | 61 | 0.050 |
Why?
| | Mentors | 1 | 2024 | 210 | 0.050 |
Why?
| | Aqueous Humor | 1 | 2022 | 38 | 0.050 |
Why?
| | Orbit | 1 | 2022 | 72 | 0.050 |
Why?
| | Phenotype | 2 | 2022 | 3160 | 0.050 |
Why?
| | Cluster Analysis | 1 | 2023 | 515 | 0.050 |
Why?
| | Drug Implants | 1 | 2022 | 83 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2022 | 150 | 0.050 |
Why?
| | Nicotine | 1 | 2005 | 347 | 0.050 |
Why?
| | Communication Barriers | 1 | 2023 | 114 | 0.050 |
Why?
| | Reference Standards | 1 | 2022 | 184 | 0.050 |
Why?
| | Capsulorhexis | 1 | 2021 | 8 | 0.040 |
Why?
| | Safety-net Providers | 1 | 2023 | 117 | 0.040 |
Why?
| | Albumins | 1 | 2022 | 116 | 0.040 |
Why?
| | Retinal Ganglion Cells | 1 | 2022 | 111 | 0.040 |
Why?
| | Morbidity | 1 | 2022 | 321 | 0.040 |
Why?
| | Fibrinogen | 1 | 2022 | 173 | 0.040 |
Why?
| | Dissent and Disputes | 1 | 2021 | 20 | 0.040 |
Why?
| | Intraoperative Period | 1 | 2020 | 67 | 0.040 |
Why?
| | Crowding | 1 | 2021 | 36 | 0.040 |
Why?
| | Smoking Cessation | 1 | 2005 | 434 | 0.040 |
Why?
| | Hepacivirus | 1 | 2022 | 263 | 0.040 |
Why?
| | Biometry | 1 | 2021 | 69 | 0.040 |
Why?
| | Myanmar | 1 | 2020 | 6 | 0.040 |
Why?
| | Myotomy | 1 | 2020 | 15 | 0.040 |
Why?
| | Vision, Binocular | 1 | 2020 | 41 | 0.040 |
Why?
| | Risk-Taking | 1 | 2003 | 345 | 0.040 |
Why?
| | Intravitreal Injections | 1 | 2020 | 60 | 0.040 |
Why?
| | Rupture | 1 | 2020 | 89 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2025 | 868 | 0.040 |
Why?
| | Eye Movements | 1 | 2020 | 82 | 0.040 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 496 | 0.040 |
Why?
| | Survival Rate | 1 | 2024 | 1935 | 0.040 |
Why?
| | HIV | 1 | 2020 | 246 | 0.040 |
Why?
| | Health Education | 1 | 2003 | 355 | 0.040 |
Why?
| | Canada | 1 | 2020 | 412 | 0.040 |
Why?
| | Chromatography, Liquid | 1 | 2021 | 450 | 0.040 |
Why?
| | Sex Factors | 1 | 2025 | 2054 | 0.040 |
Why?
| | Remission, Spontaneous | 1 | 2019 | 40 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1763 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2021 | 411 | 0.040 |
Why?
| | Microscopy, Acoustic | 1 | 2018 | 9 | 0.040 |
Why?
| | Attitude | 1 | 2021 | 261 | 0.040 |
Why?
| | Pyrimidinones | 1 | 2019 | 114 | 0.040 |
Why?
| | Ophthalmoscopy | 1 | 2018 | 38 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 142 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2023 | 1036 | 0.040 |
Why?
| | Circadian Rhythm | 1 | 2023 | 490 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 575 | 0.040 |
Why?
| | Exfoliation Syndrome | 1 | 2018 | 10 | 0.040 |
Why?
| | Corneal Pachymetry | 1 | 2018 | 15 | 0.040 |
Why?
| | Pseudophakia | 1 | 2018 | 16 | 0.040 |
Why?
| | Tandem Mass Spectrometry | 1 | 2021 | 557 | 0.040 |
Why?
| | Disease-Free Survival | 1 | 2019 | 704 | 0.030 |
Why?
| | Prosthesis Design | 1 | 2020 | 332 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2025 | 2846 | 0.030 |
Why?
| | Physical Examination | 1 | 2019 | 243 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2020 | 605 | 0.030 |
Why?
| | Ambulatory Care Facilities | 3 | 2004 | 246 | 0.030 |
Why?
| | Stents | 1 | 2021 | 529 | 0.030 |
Why?
| | Referral and Consultation | 1 | 2022 | 799 | 0.030 |
Why?
| | Sex Characteristics | 1 | 2022 | 769 | 0.030 |
Why?
| | Equipment Design | 1 | 2018 | 520 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2024 | 961 | 0.030 |
Why?
| | Sleep | 1 | 2023 | 800 | 0.030 |
Why?
| | Mental Health | 1 | 2022 | 740 | 0.030 |
Why?
| | Reproducibility of Results | 1 | 2023 | 3316 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2019 | 1498 | 0.030 |
Why?
| | Program Evaluation | 2 | 2011 | 913 | 0.030 |
Why?
| | Anxiety | 1 | 2022 | 1069 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 1014 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2024 | 1811 | 0.030 |
Why?
| | Proteomics | 1 | 2020 | 1114 | 0.030 |
Why?
| | Child Abuse | 1 | 2019 | 547 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2019 | 914 | 0.030 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1983 | 0.030 |
Why?
| | Depression | 1 | 2022 | 1467 | 0.020 |
Why?
| | Pandemics | 1 | 2021 | 1650 | 0.020 |
Why?
| | Animals | 3 | 2009 | 37351 | 0.020 |
Why?
| | Blood Glucose | 1 | 2021 | 2191 | 0.020 |
Why?
| | Legionellosis | 1 | 2011 | 2 | 0.020 |
Why?
| | Prognosis | 1 | 2019 | 4024 | 0.020 |
Why?
| | Medical Audit | 1 | 2011 | 77 | 0.020 |
Why?
| | Whooping Cough | 1 | 2011 | 56 | 0.020 |
Why?
| | Haemophilus Infections | 1 | 2011 | 41 | 0.020 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2019 | 1748 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 137 | 0.020 |
Why?
| | International Classification of Diseases | 1 | 2011 | 138 | 0.020 |
Why?
| | Cryptosporidium | 1 | 2008 | 14 | 0.020 |
Why?
| | Caliciviridae Infections | 1 | 2008 | 20 | 0.020 |
Why?
| | Norovirus | 1 | 2008 | 26 | 0.020 |
Why?
| | Aid to Families with Dependent Children | 1 | 2007 | 3 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 366 | 0.020 |
Why?
| | Faculty | 1 | 2008 | 151 | 0.020 |
Why?
| | Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2007 | 96 | 0.020 |
Why?
| | Medically Uninsured | 1 | 2007 | 134 | 0.020 |
Why?
| | Family Characteristics | 1 | 2008 | 192 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 1958 | 0.020 |
Why?
| | Pharmaceutical Preparations | 1 | 2007 | 179 | 0.010 |
Why?
| | Guideline Adherence | 1 | 2009 | 557 | 0.010 |
Why?
| | Maryland | 1 | 2005 | 59 | 0.010 |
Why?
| | Administration, Topical | 1 | 2005 | 148 | 0.010 |
Why?
| | Urban Health Services | 1 | 2004 | 66 | 0.010 |
Why?
| | Acute Disease | 1 | 2007 | 1011 | 0.010 |
Why?
| | Office Visits | 1 | 2003 | 95 | 0.010 |
Why?
| | Syphilis | 1 | 2003 | 33 | 0.010 |
Why?
| | Administration, Oral | 1 | 2005 | 790 | 0.010 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2003 | 281 | 0.010 |
Why?
| | Risk | 1 | 2004 | 913 | 0.010 |
Why?
| | Mothers | 1 | 2007 | 764 | 0.010 |
Why?
| | Urban Population | 1 | 2004 | 482 | 0.010 |
Why?
| | HIV Infections | 1 | 2003 | 2946 | 0.000 |
Why?
|
|
Patnaik's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|